Effect of Atorvastatin Calcium Combined with SacubitrilValsartan in Coronary Heart Disease Complicated with Cardiac Insufficiency

To explore the efficacy and safety of atorvastatin combined with sacubitril- valsartan in patients with coronary heart disease complicated with cardiac insufficiency. A total of 188 patients with coronary heart disease combined with cardiac dysfunction were included in this study, of which 73 patients received atorvastatin and 115 patients received atorvastatin combined with sacubitril-valsartan. According to the efficacy criteria, the efficacy of atorvastatin group and atorvastatin+sacubitril- valsartan group was determined. The changes of left ventricular mass index, left ventricular ejection fraction, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular end-diastolic volume and N-terminal pro-brain natriuretic peptide before and after treatment were detected in the two groups. The inflammatory response of patients was evaluated by comparing the changes of interleukin-6 and high-sensitivity C-reactive protein before and after treatment. Adverse reactions occurred during treatment were collected to determine the safety of treatment. Before treatment, there was clearly no significant difference between the two groups. After treatment, most of the patients in the atorvastatin and atorvastatin+sacubitril-valsartan groups showed significant efficacy, while the efficacy in the atorvastatin+sacubitril-valsartan group was better than that in the atorvastatin group. After 6 mo of treatment, left ventricular mass index, left ventricular ejection fraction, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular end-diastolic volume and N-terminal pro-brain natriuretic peptide in atorvastatin+ sacubitril-valsartan group were superior to those in atorvastatin group. At the same time, the levels of inflammatory cytokines in the atorvastatin+sacubitrilvalsartan group were obviously lower than those in the atorvastatin group after 6 mo of treatment. The adverse events that occurred during treatment in the atorvastatin and atorvastatin+ sacubitril- valsartan groups mainly included hypotension, hyperkalemia, fecal occult blood, hematuria and arrhythmia. There was no significant difference in the incidence of adverse reactions in the atorvastatin+sacubitrilvalsartan group compared with the atorvastatin group. The efficacy of atorvastatin plus sacubitrilvalsartan group was higher than that of atorvastatin group. Atorvastatin combined with sacubitrilvalsartan has a significant effect on patients with cor onary heart disease and cardiac insufficiency.